Despite challenges such as normal tissue toxicity and tumor heterogeneity, precise regulation of SLC7A11 has become a key direction for overcoming treatment resistance, enhancing sensitivity to ferroptosis, and optimizing metabolic-immune combination therapies. Here, SLC7A11 is linked to neoplasm.